CBER Strategic Plan Showcases New Lab Complex, Research Projects For Cancer, Rare Diseases
Executive Summary
Center for Biologics Evaluation and Research describes the Life Sciences-Biodefense Laboratory scheduled for completion in December 2013 and its plans to facilitate development of safe and effective products.
You may also be interested in...
GDUFA Commitments Won’t Be Met If Congress Nixes White Oak Funding
President Obama’s FY 2014 budget proposal argues that Congressional failure to provide FDA with additional funding for its White Oak consolidation efforts could force GDUFA hiring to stall, jeopardizing the agency’s ability to meet the user fee commitments negotiated with industry.
Revising The Blueprint: FDA HQ Construction Nears Completion, But Some Planned Buildings On Hold
The Life Sciences-Biodefense lab complex would remain on schedule for completion in FY 2014, but communications and logistical buildings included in the campus master plan would be on hold.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.